Gsk (GLAXF) Non-Current Deffered Revenue (2017 - 2018)
Gsk (GLAXF) recorded quarterly Non-Current Deffered Revenue of $24.4 million in Q4 2018, down 16.3% quarter-over-quarter from $29.2 million in Q4 2017, and down 16.3% on a YoY basis from $29.2 million in Q4 2017.
Gsk (GLAXF) Non-Current Deffered Revenue (2017 - 2018) Analysis & Trends
Gsk's Non-Current Deffered Revenue history runs 2 years deep, the most recent figure standing at $24.4 million for Q4 2018.
- In Q4 2018, Non-Current Deffered Revenue fell 16.3% year-over-year to $24.4 million; the TTM figure through Dec 2018 stood at $24.4 million (down 16.3% YoY), while the FY2018 annual figure was $25.4 million, down 10.46% from the prior year.
- Non-Current Deffered Revenue was $24.4 million for Q4 2018 at Gsk, down from $29.2 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $29.2 million in Q4 2017 to a low of $24.4 million in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | - |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | - |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | - |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | - |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | - |
| 10 | Gsk | - | - | 7.76 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 24.45 Mn |
| Dec 31, 2017 | 29.21 Mn |